

REQUEST FOR PROPOSALS (RFP)

For Synoptic Evaluation

RFP No. RP430-2020-01

ISSUE DATE:	Tuesday May 19, 2020
DEADLINE FOR PROPONENT ENQUIRIES	Monday June 1, 2020, by 5:00pm ET (Toronto local time)
DEADLINE FOR ISSUING ADDENDA & RESPONSES TO PROPONENT ENQUIRIES	Wednesday June 3, 2020
PROPOSAL SUBMISSION DEADLINE	Wednesday June 10, 2020 no later than 3:00pm ET (Toronto local time)
PROPONENT INTERVIEWS	Thursday July 9 and Friday July 10, 2020

PROPONENT ENQUIRIES <u>only</u> by e-mail to: procurement@partnershipagainstcancer.ca

This Request for Proposals is the exclusive property of the Canadian Partnership Against Cancer (the Partnership), all rights reserved. The release, reproduction, distribution or other use without the express written consent of the Partnership is strictly prohibited.

^{**}Proponents should reference this RFP number (RFP No. RP430-2020-01) in the subject line of their correspondence. **

DISCLAIMER

The Partnership disclaims responsibility for all warranties and conditions with regard to electronic files and any contents thereof. The Partnership makes no guarantee or representation that electronic files are error-free, nor compatible with recipient's systems, nor free from viruses. The Partnership will not be held responsible for any problems or injuries that arise including, but not limited to, the reliability or safety, of the use of its electronic files, in whole or in part.

About the Canadian Partnership Against Cancer

As the steward of the <u>Canadian Strategy for Cancer Control</u>, the Partnership works with partners to reduce the burden of cancer on Canadians. Our partner network - cancer agencies, health system leaders and experts, and people affected by cancer - brings a wide variety of expertise to every aspect of our work. After 10 years of collaboration, we are accelerating work that improves the effectiveness and efficiency of the cancer control system, aligning shared priorities and mobilizing positive change across the cancer continuum. From 2017-2022, our work is organized under five themes in our <u>Strategic Plan</u>: quality, equity, seamless patient experience, maximize data impact, sustainable system. The Partnership continues to support the work of the collective cancer community in achieving our shared 30-year goals: a future in which fewer people get cancer, fewer die from cancer and those living with the disease have a better quality of life. The Partnership was created by the federal government in 2006 to move the Strategy into action and receives ongoing funding from Health Canada to continue leading the Strategy with partners from across Canada. Visit www.partnershipagainstcancer.ca.



Table of Contents

DISCLA	4IMER	.2
1.0	INSTRUCTION TO PROPONENTS	5
1.1	Invitation to Proponents	5
1.2	Enquiries	5
1.3	Proposal Submission	5
1.4	Amendment and Withdrawal of Proposal	6
1.5	Agreement for Deliverables	6
1.6	No Guarantee of Volume of Work or Exclusivity of Agreement	6
1.7	RFP Timetable	7
1.8	Proposal Content	7
1.9	Pricing and Timing	7
1.10	Key Personnel	8
1.11	AODA Compliance Legislation	8
1.12	Evaluation Process and Criteria	8
1.12.1	. Mandatory Criteria	8
1.12.2	. Rating Criteria	8
1.12.3	. Stages of the Proposal Evaluation	.10
1.13	Negotiations and Finalization of Agreement	.11
2.0	SUPPLEMENTARY TERMS AND CONDITIONS	12
2.1	All New Information to Proponents by way of Addenda	.12
2.2	Retention and Disclosure of Proposals	.12
2.3	Governing Law of RFP Process	.12
2.4	Proponents to Follow Instructions	.12



2.5	Proponents Shall Bear Their Own Costs	12
2.6	Communication after Issuance of RFP	.12
2.7	Verify, Clarify and Supplement	13
2.8	Confidentiality	13
2.9	Disqualification	.13
2.10	Procurement Process Non-Binding	.14
SCHED	ULE A - SERVICES AND DELIVERABLES	15
Bait ar	nd Switch	.22
SCHED	ULE B - SUBMISSION FORM	23
SCHED	ULE C - PRICING SHEET	27
SCHED	ULE D - REFERENCE FORM	29
SCHED	ULE E - PROJECT DELIVERABLES AND MILESTONES	32
SCHED	ULE F - ADDITIONAL TERMS AND CONDITIONS FOR AGREEMENTS	33



1.0 INSTRUCTION TO PROPONENTS

1.1 Invitation to Proponents

This Request for Proposals ("RFP") is an invitation to suppliers/vendors (the "Proponents") to submit proposals (the "Proposals") for the services and deliverables described in Schedule A (the "Deliverables"). This RFP is issued by the Canadian Partnership Against Cancer (the "Partnership"), a not-for-profit corporation funded by Health Canada.

1.2 Enquiries

Proponents should forward all enquiries and other communications, via e-mail only to:

procurement@partnershipagainstcancer.ca

All enquiries should be made via e-mail to the e-mail address above and enquiries submitted in any other way will not be accepted or answered. Proponents acknowledge that all enquiries received from Proponents and corresponding responses provided by the Partnership will be disclosed to all Proponents by way of an Addendum.

All enquiries and communications should be received prior to the Deadline for Proponent Enquiries set out in Section 1.7.

1.3 Proposal Submission

Proponents should submit their Proposals in two separate parts. The financial part will contain the price portion of the Proposal using the Pricing Sheet, in Schedule C. The technical part of will contain the rest of the Proposal. Each part should be submitted in separate sealed electronic file in accordance with the instructions in this section.

Proponents must submit the Proposal in electronic copy in Microsoft Word format or portable document format (PDF), by e-mail to the e-mail address shown below before the Proposal Submission Deadline.

E-mail: procurement@partnershipagainstcancer.ca

Proposals submitted in any other manner will not be accepted.

It is the sole responsibility of the Proponent to ensure that its Proposal is received by the Partnership before the Proposal Submission Deadline.



1.4 Amendment and Withdrawal of Proposal

Proponents may amend their Proposals prior to the Proposal Submission Deadline by withdrawing a submitted Proposal and resubmitting the amended Proposal prior to the Proposal Submission Deadline.

At any time throughout the RFP process until the execution of a written agreement for provision of the Deliverables, the Proponent may withdraw its Proposal. To withdraw the Proposal, a notice of withdrawal signed by an authorized representative of the Proponent must be sent to:

procurement@partnershipagainstcancer.ca

The Partnership is under no obligation to return withdrawn Proposals.

1.5 Agreement for Deliverables

The selected Proponent will be invited to enter into an agreement (the "Agreement") with the Partnership for the provision of the Deliverables. The final terms of the Agreement may be negotiated with the selected Proponent. However, Proponents are advised that the Agreement is expected to include the terms and conditions set out in Schedule F to this RFP.

It is the Partnership's intention to enter into an Agreement with only one (1) legal entity. The term of the Agreement is to be for a period of up to **nineteen (19) months** with an option in favour of the Partnership to renew or extend the Agreement on the same terms and conditions up to an additional term of up to **three (3) months**.

1.6 No Guarantee of Volume of Work or Exclusivity of Agreement

The Partnership makes no guarantee of the value or volume of work to be assigned to any Proponent. Any Agreement executed with a selected Proponent will not be an exclusive contract for the provision of the described services and deliverables. The Partnership may contract with others for the same or similar services and deliverables to those described in this RFP or may obtain the same or similar services and deliverables internally.



1.7 RFP Timetable

The following is the schedule for this RFP:

ISSUE DATE:	Tuesday May 19, 2020
DEADLINE FOR PROPONENT ENQUIRIES	Monday June 1 st , 2020, by 5:00pm ET (Toronto local time)
DEADLINE FOR ISSUING ADDENDA & RESPONSES TO PROPONENT ENQUIRIES	Wednesday June 3, 2020
PROPOSAL SUBMISSION DEADLINE	Wednesday June 10, 2020 no later than 3:00pm ET (Toronto local time)
PROPONENT INTERVIEWS	Thursday July 9 and Friday July 10, 2020

The Partnership may amend the schedule for this RFP in its sole discretion at any time prior to the Proposal Submission Deadline.

1.8 Proposal Content

The Proposal should be brief (max 10 pages single spaced, not including appendices) and include:

- a brief statement demonstrating a fair understanding of the evaluation topic and the need to address the scope of work
- a brief description of how the Proponents' skills and experience could be applied to this RFP to deliver on the scope of work
- demonstrate experience with projects of similar nature
- a description of the approach that will be taken to complete the deliverables, along with high level timelines
- proposed cost for the work and any assumptions used to derive the budget (i.e. estimated number of days of work, level of effort and team composition)
- a statement as to what approach the Proponent would consider working with the Partnership to engage the stakeholders and conduct the evaluation; and as to whether the Proponent can meet the timelines.

1.9 Pricing and Timing

Please submit the price for completion of this project (both fees and expenses). The Proponent should assume that it is required to supply all necessary professional staff to undertake the project. The Proponent shall provide *a firm maximum ceiling price* for the assignment and a proposed payment schedule, if applicable. The Proponent should submit pricing (Schedule C) in a separate electronic file from the rest of the Proposal (see Section 1.3).



1.10 Key Personnel

The key personnel who are named in the Proposal will be expected to remain assigned for the duration of the project, unless otherwise agreed to in writing by the Partnership. In the event the Proponent wishes to substitute any of the key personnel, the individual(s) proposed would have to demonstrate similar qualifications and experience as required to successfully perform such duties. Under the Agreement, the Partnership will have the sole right to determine whether key personnel proposed as substitutes are qualified to work on the project.

1.11 AODA Compliance Legislation

As part of its response to this RFP, a Proponent may describe all measures that the Proponent intends to implement or make available in order that the Deliverables provided in response to this RFP be in compliance with applicable standards under the Accessibility for Ontarians with Disabilities Act, 2005 ("AODA") and its regulations, including but not limited to (i) any training that has been, or will be, provided to Proponent's staff; and (ii) all policies implemented by the Proponent in respect of the AODA and its regulations. The Agreement will require that the successful Proponent provide all Deliverables in accordance with AODA and its regulations.

1.12 Evaluation Process and Criteria

Proposals will be reviewed and evaluated by an evaluation committee which is comprised of representatives of the Partnership and may include external advisors (the "Evaluation Committee").

1.12.1. Mandatory Criteria

First, the Partnership will evaluate Proposals for compliance with the following Mandatory Criteria:

MANDATORY FORMS:
Submission Form (Schedule B)
Pricing Sheet (Schedule C)
References (Schedule D)
Deliverables and Milestones (Schedule E) (for Project RFP's or as requested)

1.12.2. Rating Criteria

Next, the Partnership will evaluate and score Proposals based on the following rating criteria:



SYNOPTIC QUALITY IMPROVEMENT PROJECTS EVALUATION CRITERIA	Weighting
 Qualifications and experience of proponent and key members of the proposed team Experience working with cancer agencies, health authorities and organizations, and/or front-line health care staff including clinicians, nurses, etc. Conducting systematic pan-Canadian evaluations within the public sector, involving complex clinical interventions and/or models of care in multiple jurisdictions and hospitals Evaluating variety of initiatives on the ground improving quality of care and improving patient outcomes Evaluating pilots, scale up and spread of an intervention, and/or system level impact, across jurisdictions Implementing evaluations using: large-scale qualitative data collection and thematic analysis. quantitative data collection; statistical analysis using administrative or third-party data, survey data; and qualitative mixed methods design; triangulation of data Development of qualitative tools such as semi structured interview guides, focus group facilitation questions and using tools in practice 	25%
 Quality of the proposed approach and work plan (adequacy of project team structure, work plan, client engagement, reporting and controls, likelihood of timely delivery) Proposed approach to gather high quality and consistent qualitative evaluation data from various participants Proposed approach to analyze and synthesize all quantitative and qualitative data, approach to triangulate where appropriate. Proposed engagement approach with funded partners, evaluation participants and Partnership team across Phase1-3. Feasibility of overall approach, and understanding of the portfolio Likelihood of timely delivery 	
 Interviews with the Proponent organization and team Discuss qualifications, experiences, methodology to complete scope of work and overall fit 	30%



Thoughtful and high-quality discussion that demonstrates strong understanding of and provides insight on the needs articulated in the RFP and the context for evaluation	
Proposed Budget	20%
Total	100%

1.12.3. Stages of the Proposal Evaluation

The Partnership will conduct the evaluation of Proposals in the following three (3) stages:

Stage I

Stage I will consist of a review to determine which Proposals comply with all of the Mandatory Criteria. If a Proposal fails to satisfy all of the Mandatory Criteria, the Partnership will issue the Proponent a rectification notice identifying the deficiencies and providing the Proponent an opportunity to rectify the deficiencies within a period of 2 business days from the date of the notice (the "Rectification Period"). If the Proponent fails to satisfy all of the Mandatory Criteria within the Rectification Period, the Proposal will be disqualified. If a Proposal is disqualified, it will not be further evaluated.

Stage II

Stage II will consist of a scoring by the Partnership of each qualified Proposal on the basis of the rating criteria. The Partnership may shortlist the top scoring Proposals and the Proponents may be invited to an interview at the Partnership offices or virtually. Interviews to be scheduled, at a time that is convenient for the Partnership.

Stage III

Stage III will consist of a scoring of the pricing submitted. The evaluation of price may be undertaken after the evaluation of mandatory criteria (Stage I) and any rated criteria (Stage II) has been completed.

The formula to be used for scoring price is as follows:

 $Proponent's \ price \ score = lowest \ proposal \ price \div Proponent's \ price \times weighting$



Cumulative Score

At the conclusion of Stage III, the scores from Stage II and Stage III will be added and, subject to satisfactory reference checks, the highest scoring Proposal will be selected, and the Proponent of that Proposal will be invited to finalize and enter into the Agreement.

1.13 Negotiations and Finalization of Agreement

The final terms of the Agreement may be negotiated with the selected Proponent. However, Proponents are advised that the Agreement is expected to include the terms and conditions set out in Schedule F to this RFP.

Any negotiations will not constitute a legally binding offer to enter into a contract on the part of the Partnership or the Proponent and there will be no legally binding relationship created with any Proponent prior to the execution of a written agreement. Negotiations may include requests by the Partnership for supplementary information from the Proponent to verify, clarify or supplement the information provided in its Proposal or to confirm the conclusions reached in the evaluation, and may include requests by the Partnership for improved pricing or performance terms from the Proponent.

The Partnership intends to conclude negotiations and finalize the agreement with the selected Proponent within 30 days from the date the Partnership invites the selected Proponent to enter negotiations.

If the parties cannot conclude negotiations and finalize the agreement for the Deliverables within the that time period, the Partnership may discontinue negotiations with the selected Proponent and may cancel the RFP process or invite the next-highest-scoring Proponent to enter into negotiations. This process will continue until an agreement is finalized or until the Partnership elects to cancel the RFP process.



2.0 SUPPLEMENTARY TERMS AND CONDITIONS

2.1 All New Information to Proponents by way of Addenda

This RFP may be amended only by a written addendum (an "Addendum") in accordance with this section. If the Partnership, for any reason, determines that it is necessary to provide additional information relating to this RFP, such information will be communicated to all Proponents by Addenda made available to all Proponents in the same way as the original RFP. Each Addendum shall form an integral part of this RFP. Any amendments or supplements to this RFP made in any other manner shall not be binding. It is the sole responsibility of the Proponent to ensure that it has received all Addenda pertaining to this RFP. The Partnership will not take any responsibility for losses, misunderstandings, errors or omissions from the Proponent not having received or reviewed any and all Addenda.

2.2 Retention and Disclosure of Proposals

All information obtained by the Partnership from Proponents in connection with this RFP will be retained by the Partnership for internal purposes. Information provided by Proponents in response to this RFP may be disclosed by the Partnership if permitted or required by law.

2.3 Governing Law of RFP Process

The RFP process shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein.

2.4 Proponents to Follow Instructions

Proponents should structure their Proposals in accordance with the instructions in this RFP. Where information is requested in this RFP, any response made in a Proposal should reference the applicable section numbers of this RFP where that request was made. Proponents responding to the RFP should provide additional information related to contacts and their corporate identity and status.

2.5 Proponents Shall Bear Their Own Costs

The Proponent shall bear all of its own costs associated with or incurred in the preparation, presentation and submission of its Proposal including, if applicable, costs incurred for interviews, site visits or demonstrations.

2.6 Communication after Issuance of RFP

Proponents should promptly examine all of the documents comprising this RFP and report any errors, omissions or ambiguities. Proponents may direct questions or seek additional information by e-mail to the e-mail address set out in Section 1.2, before the Deadline for



Proponent Enquiries set out in Section 1.7. No such communications are to be directed to the Partnership in any other manner. It is the responsibility of the Proponent to seek clarification from the Partnership on any matter it considers to be unclear. The Partnership is under no obligation to provide additional information; but, may do so at its sole discretion.

2.7 Verify, Clarify and Supplement

In the evaluation process, the Partnership may:

- request further information from the Proponent or third parties in order to verify, clarify or supplement the information provided in the Proposal;
- interview any or all Proponents to obtain information about or clarification of their Proposals;
- check references other than those provided by any Proponent; and
- consider the Proponent's past performance or conduct on previous contracts with the Partnership or other institutions.

The Partnership may revisit, re-evaluate, rescore or reject the Proponent's Proposal on the basis of any such information.

2.8 Confidentiality

All information received by the Proponent provided by or obtained from the Partnership in any form in connection with this RFP either before or after the issuance of this RFP:

- is the sole property of the Partnership and must be treated as confidential;
- is not to be used for any purpose other than replying to this RFP and the performance of any subsequent Agreement; and
- shall be returned by the Proponent to the Partnership immediately upon the request of the Partnership.

2.9 Disqualification

The Partnership may disqualify a Proposal on grounds of faulty submission, conflict of interest, improper conduct or provision of inaccurate or misleading information by the Proponent.



2.10 Procurement Process Non-Binding

This procurement process is not intended to create and will not create a formal, legally binding bidding process and will instead be governed by the law applicable to direct commercial negotiations. For greater certainty and without limitation:

- (a) this RFP will not give rise to any Contract A-based tendering law duties or any other legal obligations arising out of any process contract or collateral contract; and
- (b) neither the Proponent nor the Partnership will have the right to make any claims (in contract, tort, or otherwise) against the other with respect to the award of a contract, failure to award a contract or failure to honour a Proposal submitted in response to this RFP.

No legal relationship or obligation regarding the procurement of any good or service will be created between the Proponent and the Partnership by this RFP process until the successful negotiation and execution of a written agreement for the acquisition of such goods and/or services.

While the pricing information provided in Proposals will be non-binding prior to the execution of a written agreement, such information will be assessed during the evaluation of the Proposals and the ranking of the Proponents. Any inaccurate, misleading or incomplete information, including withdrawn or altered pricing, could adversely impact any such evaluation or ranking or the decision of the Partnership to enter into an agreement for the Deliverables.

The Partnership may cancel or amend the RFP process without liability at any time.



SCHEDULE A - Services and Deliverables

Background

From 2007 to 2017, with funding support from the Partnership, multiple provinces implemented information systems to enable pathologists and surgeons to electronically collect discrete (synoptic) data related to cancer diagnosis and surgical treatment. In the clinical setting, the pathology and surgical synoptic reports are used to promote communication among clinicians in a timely manner to drive downstream patient care activities. For example, since the implementation of synoptic reporting, the turnaround time for the majority of the pathology reports is 14 days and 97% of the inter-operative surgical reports are transmitted to patient files within 24 hours.

Recent funding support from the Partnership, which began in 2017, aims at supporting eight jurisdictions (six (6) project teams) to use synoptic data and evidence-based methodologies to:

- Standardize care processes and practices, and build a foundation for continuous culture of quality improvement by engaging physicians and interdisciplinary teams in driving innovations in care through implementation of quality improvement initiatives
- Influence uptake of evidence (real world data) to inform health system planning by facilitating a dialogue with decision-makers

Intervention

All 6 synoptic projects received funding from the Partnership to:

 Lead engagement and change by convening key stakeholders, using comparative feedback reports and quality improvement (QI) approaches. Implement and sustain change driven by implementation of quality improvement initiatives and establishing culture and structures to support continuous quality improvement and inform health system planning.

In addition, all 6 project teams received coaching from several clinical and quality improvement experts who offered advice and guided the project teams to strategize and implement approaches designed to:

- effectively lead change
- engage physicians and other stakeholders
- convene clinician forums and facilitate groups to form consensus and act
- mobilize knowledge (integrating real world data with evidence from the literature) across a variety of stakeholders
- build a sustainable culture and support for continuous quality improvement



Outcomes:

The 6 funded projects are to be completed by March 31, 2022 (some have been more recently impacted by the COVID-19 pandemic than others). These 6 projects are accountable to achieve the following program level outcomes:

- 1. Effectively leverage synoptic data through feedback reports to identify and address gaps in delivering standardized high-quality diagnosis and treatment to patients
- 2. Form consensus among pathologists and surgeons on gaps which inform implementation of quality improvement initiatives
- 3. Enable pathologists and surgeons to adopt evidence-based practice changes catalyzed by implementation of quality improvement work
- 4. Influence uptake of evidence to inform health system planning and standardize clinical practice.

Through these outcomes, the 6 projects will contribute towards the Partnership's cancer control short-term (2022), intermediate term (2027), and long-term outcomes (2037):



2022

Canadians who might have cancer are diagnosed sooner and patients with cancer get safe, fast quality care



2027

More patients will be receiving better, faster, safer screening, diagnosis and treatment, and Canada's cancer system will be more efficient and sustainable



2037

Fewer Canadians will die from cancer

Terms of Reference

The Partnership is responsible for:

- Collection of all quantitative data
 - Leading engagement efforts with funded partners
 - Providing specifics on evaluation vision, expectations and quality

The successful Proponent is responsible for:

- Developing evaluation execution project plan/ timeline, role, stakeholder engagement process/ method and workback schedule
- Developing qualitative data collection tools
- Supporting engagement efforts with funded partners and engagement materials
- > Collection and analysis of qualitative data
- Analysis of quantitative data provided by the Partnership
- Delivery of final evaluation products



2. Evaluation Rationale

Evaluation is an important tool that is used to support decision-making. The objectives of this evaluation are to:

- Demonstrate the outcomes of implementing synoptic data-driven quality improvement initiatives and the benefits to cancer health systems
- Use real world evidence to inform decisions within participating organizations and of future work at the Partnership
- Share lessons learned (e.g., barriers and facilitators) to advance and sustain a culture of quality improvement within cancer care settings.

3. Audiences and Intended Uses Primary:

The Partnership, and its programs:

The Partnership is responsible for reporting back on the results of its work to its funder Health Canada, and its Board of Directors. It is anticipated due to the novel approach to this work, and the potential future investment in quality improvement across the cancer control continuum, that results and lessons learned will also be of value in informing future work.

Synoptic Funded Partners Funded Partners:

It is anticipated that evaluation results will be leveraged by partners to demonstrate their individual project improvement in cancer care delivery quality occurring as a result of QI work to secure resources, funding, or infrastructure to support sustainability of QI. Additionally, results can be used to support local or regional decision making, health system planning, and the advancement of QI culture within organizations and/or across jurisdictions.

Secondary:

Canadian clinicians/organizations interested in conducting Quality Improvement (QI) initiatives (non-funded)

It is also the interest of this evaluation to generate insights, tools, and methodologies that other Canadian clinicians/organizations can leverage should they be interested in conducting OI initiatives.

c. Evaluation Questions

Five (5) overarching evaluation questions were generated that will guide the evaluation plan:

- 1. To what extent has data been used to effectively inform gaps in care and QI projects?
- 2. To what extent have the right stakeholders been effectively engaged in order to mobilize evidence-based practice data to 1) address QI gaps 2) advance the consistent clinical practice?
- 3. To what extent has this work signaled shifts in culture particular to jurisdictional QI in the treatment of patients?
- 4. To what extent has the Partnership effectively supported jurisdictions to advance implementation of QI initiatives?

Canadian Partnership Against Cancer RFP# RP430-2020-01 Issued: May 19, 2020



5. In what ways has each QI intervention contributed to eliminating low benefit practices and adopting high-value practices?

4. Evaluation Design and Methodology

a) Design

The Partnership is taking a coordinated approach to evaluate 6 funded projects using a pragmatic approach to:

- Seek collective perspectives and data consistently
- Analyze quantitative clinical and quality improvement initiative performance measures (observe changes over specific time points)
- Capture common and distinct lessons associated with implementing quality improvement initiatives across multiple jurisdictions.

While the 6 funded partners have implemented different QI initiatives, they are accountable for executing a core set of activities (see section on Intervention).

b) Data collection methods and analysis

Both quantitative and qualitative data will be collected in order to answer evaluation questions and demonstrate results of the work. Where feasible, data will be collected consistently to allow for aggregation.

Quantitative Data

- 1. Pre-determined quantitative measures will be leveraged from provincial Pre-determined quantitative measures will be leveraged from provincial administrative data sets and collected at baseline, time 1 and time 2. Summary statistics and analysis looking at changes over time will be reported. Such measures are specific to the quality improvement focus of each funded partner (e.g. percentage change in re-excision rates for breast cancer) and are collected in order to demonstrate potential changes in clinical performance occurred over time. Each funded project will encompass both process measures specific to the QI project, as well as balancing measures An average of 5 measures will be collected per project.
- 2. Eight (8) pre-determined performance indicators will be collected from all partners at various timepoints that measure progress toward achieving key activities and targets. (E.g. Proportion of clinicians attending Community of Practice events)
- 3. Standardized community of practice survey responses will be collected from clinicians and key stakeholders at various timepoints across the project lifecycle that speak to clinical engagement and uptake of QI methodology. Responses will be aggregated and analyzed for major trends, and comparison across jurisdictions in the following domains; usefulness of data, frequency of use, motivation to participate, influence on modifying clinical practice, understanding of QI, and overall satisfaction.



4. Standardized survey responses will be collected from participating clinicians across projects at 1 point in time. The survey will seek to gather the perspectives of clinicians participating in disease-site specific quality improvement projects in order to understand observed barriers and facilitators to implementation within their clinical setting. Responses will be aggregated and analyzed for major trends. It should be noted that the tools itself must be created therefore analysis of data will depend on the survey's design. This approach may be subject to change upon consultation with partners.

The Partnership takes responsibility of collecting all quantitative data from funded partners and providing to the successful proponent for analysis

Qualitative Data

Perspectives will be collected from key stakeholder groups (clinician leads, project administrators, engaged experts) via focus groups and semi-structured interviews in order to gather insights on observed behaviour change, conditions necessary for successful implementation, and the support received to implement the QI initiative. Responses will be analyzed qualitatively using thematic analysis.

Summary of Evaluation inputs:

Inputs	Measurement approach
Performance Indicators (e.g. percentage of pathologists using Synoptic feedback reports)	
Community of Practice Survey Data	Consistent tools and measures used
Focus Group discussions	across all projects
Clinician QI Experience Survey Data	
Project-specific performance measures based on QI focus	Measures are specific to the defined quality improvement project implemented using Plan Do Study Act methodology

c) Methodological limitations

- No formal control will be used to compare against results of this evaluation
- Potential for small survey response rate among participating clinicians
- Funded partners will contribute to the planning and will contribute data inputs (where feasible) to support the evaluation.



• Some partners are conducting their own project specific evaluation and economic evaluations. If project specific evaluations are not planned, partners will work with The Partnership to identify opportunities to contribute required data, where feasible.

6. Evaluation Team Composition Experience

The successful Proponent should demonstrate their evaluation experience in the following either at a team or individual level:

- Conducting systematic pan-Canadian evaluations within public sector, involving complex clinical interventions and/or models of care in multiple jurisdictions at the provincial, regional and local levels (e.g. hospitals, community agency)
- Evaluating variety of initiatives on the ground improving quality of care and improving patient outcomes
- Evaluating pilots, scale up and spread of an intervention, and/or system level impact, across jurisdictions
- Experience working with cancer agencies, health authorities and organizations, and/or front-line health care staff including clinicians, nurses, etc.
- Development of qualitative tools such as semi-structured interview guides, focus group facilitation questions
- Implementing evaluations using:
 - o large-scale qualitative data collection and thematic analysis;
 - quantitative data collection; statistical analysis using administrative or thirdparty data, survey data; and
 - o qualitative mixed methods design; triangulation of data

7. Evaluation Management

Phase 1 - Final evaluation planning and logistics (September 2020-December 2021)

- 1. Kick off meeting (post contract signing) to set out project evaluation plan (e.g., timelines, deliverables, and scope) and stakeholder engagement plan (for virtual or in-person)
- 2. Regularly scheduled touchpoint meetings through project duration, develop meeting agenda and materials
- 3. Detailed workplan and engagement plan across phase 1-3 outlining key deliverable dates, analysis plan, and touchpoint meetings and review times
- 4. Development of qualitative data collection tools (1 focus group questions, 2 semi-structured interview guides)
- 5. Development of Clinician QI experience survey (particiating clinicians)
- 6. Development of methods to integrate qualitative and quantitative data analysis

Phase 2 - Evaluation Implementation (January 2021-December 2021)

- 1. Qualitative data collection;
 - a. In-person focus group sessions at pre-scheduled in-person events (2)
 - b. Semi-structured interviews with expert coaches (virtual)

Canadian Partnership Against Cancer RFP# RP430-2020-01 Issued: May 19, 2020



Phase 3 - Evaluation Analysis and Synthesis (December 2021 - March 2022)

- 1. Draft preliminary analysis and draft product(s) for review
- 2. Concise report summarizing the methods, findings and interpretation of the findings for: The Partnership, Board of Directors, Synoptic funded partners, Jurisdictions/targeted organizations
- 3. Summary deck highlighting key messages
- 4. Presentation of findings back to the Partnership
- 5. Presentation to partners and relevant stakeholders (virtual)

a) Scheduling/timeline

Timeline date ranges may be modified based on COVID related delays

Key activities relevant to evaluation planning and implementation	Timeline
Kick off meeting with the Partnership and the successful Proponent	September 2020
Qualitative tool development, validation/engagement with partners and the Partnership Evaluation Team	September 2020-December 2020
Collection of quantitative data: QI performance measures, performance indicators, survey data at various and multiple points in time (collected by the Partnership)	October 2020 - August 2021
Collection of qualitative data: Semi structured interviews, focus groups	March 2021 - August 2021
Partner engagement meeting(s)	Will be rescheduled due to COVID- related delays
Partner projects end:	Partner project end dates are currently being reassessed due to COVID related delays. However, all projects It is anticipated that all partner projects end by Q1 of the 2021/2022 fiscal year



Bait and Switch

The successful Proponent will provide for the duration of the project, the full complement of staff required to perform the work of the project, including the specific individuals identified in its Proposal.

These key personnel shall remain assigned for the duration of the project, unless otherwise agreed to in writing by the Partnership. In the event the Proponent wishes to substitute any of the key personnel, the individual(s) proposed should demonstrate similar qualifications and experience as required to successfully perform such duties. The Partnership shall have the sole right to determine whether key personnel proposed as substitutes are qualified to work on the project. The Partnership shall not unreasonably withhold approval of staff changes.



SCHEDULE B - Submission Form

The Proponent must not amend this Form in any way other than by providing the requested information. This form must be completed, signed and submitted as part of the Proponent's Proposal.

	e Canadian Partnership Against Cancer:
I. Pi	roponent Information
(a)	The full legal name of the Proponent is:
(b)	Any other relevant name under which the Proponent carries on business is:
(c)	The jurisdiction under which the Proponent is governed is:
(d)	The name, address, telephone, facsimile number and e-mail address of the contact person for the Proponent is:
(e)	The Proponent is:
	Proponents must select one of the following choices. an individual {Provide HST/GST #} a sole proprietorship {Provide HST/GST #} a corporation {Provide HST/GST #} a partnership {Provide HST/GST #} a joint venture {Provide HST/GST #} an incorporated consortium {Provide HST/GST #}
	 a consortium that is a partnership {Provide HST/GST #} other legally recognized entity: {Specify type, provide HST/GST # or state "N/A".}

2. Acknowledgment of Non-Binding Procurement Process

The Proponent acknowledges that the RFP process will be governed by the terms and conditions of the RFP, and that, among other things, such terms and conditions confirm that this procurement process does not constitute a formal, legally binding bidding process (and



for greater certainty, does not give rise to a Contract A bidding process contract), and that no legal relationship or obligation regarding the procurement of any good or service will be created between the Partnership and the Proponent unless and until the Partnership and the Proponent execute a written agreement for the Deliverables.

3. Ability to Provide Deliverables

The Proponent has carefully examined the RFP documents and has a clear and comprehensive knowledge of the Deliverables required. The Proponent represents and warrants its ability to provide the Deliverables in accordance with the requirements of the RFP for the rates set out in its Proposal.

4. Price

The Proponent has submitted its price in accordance with the instructions in the RFP and in the form set out at Schedule C.

5. Addenda

The Proponent is deemed to have read and accepted all Addenda issued by the Partnership prior to the Deadline for Issuing Addenda. The onus remains on the Proponent to make any necessary amendments to the Proposal based on the Addenda. The Proponent confirms that it has received the following Addenda:

{List Addenda numbers or, if no Addenda were issued, state "None".}	
	,

6. Conflict of Interest

The Proponent, by submitting the Proposal, confirms that to its best knowledge and belief no actual or potential Conflict of Interest exists with respect to the submission of the Proposal or performance of the contemplated Agreement other than those disclosed in this Submission Form. Where the Partnership discovers a Proponent's failure to disclose all actual or potential Conflicts of Interest, the Partnership may disqualify the Proponent or terminate any Agreement awarded to that Proponent as a result of this procurement process.

Conflict of Interest includes, but is not limited to, any situation or circumstance where:

- a) in relation to the RFP process, the Proponent has an unfair advantage or engages in conduct, directly or indirectly, that may give it an unfair advantage, including but not limited to
 - i. having or having access to information in the preparation of its Proposal that is confidential to the Partnership and not available to other Proponents;

Canadian Partnership Against Cancer RFP# RP430-2020-01 Issued: May 19, 2020



- ii. communicating with any person with a view to influencing preferred treatment in the RFP process; or
- iii. engaging in conduct that compromises or could be seen to compromise the integrity of the RFP process and render that process non-competitive and unfair; or
- b) in relation to the performance of its contractual obligations under the Agreement, the supplier's other commitments, relationships or financial interests
 - i. could or could be seen to exercise an improper influence over the objective, unbiased and impartial exercise of its independent judgment; or
 - ii. could or could be seen to compromise, impair or be incompatible with the effective performance of its contractual obligations;

Proponents must choose one of the following two options.

The Proponent declares that: (1) there was no Conflict of Interest in preparing its Proposal; and (2) there is no foreseeable Conflict of Interest in performing the contractual obligations contemplated in the RFP. OR
The Proponent declares that there is an actual or potential Conflict of Interest relating to the preparation of its Proposal, and/or the Proponent foresees an actual or potential Conflict of Interest in performing the contractual obligations contemplated in the RFP. The details of the actual or potential Conflict of Interest are as follows:

7. Disclosure of Information

The Proponent hereby agrees that any information provided in this Proposal, even if it is identified as being supplied in confidence, may be disclosed where required by law or if required by order of a court or tribunal. The Proponent hereby consents to the disclosure, on a confidential basis, of this Proposal by the Partnership to its advisers retained for the purpose of evaluating or participating in the evaluation of this Proposal. The Proponent acknowledges that the Partnership may make public the name of any and all Proponents.



I confirm that this Submission Form has been completed with no changes to the text provided in the RFP.

Signature of Witness:	Signature of Proponent representative:
Signature of Withhest	Digitatare of Froponetic representatives
Name of Witness:	Name and Title of Proponent representative:
Traine of Withess.	rame and trace of troponent representative.
	_
	Date:
	I have authority to hind the Proponent
	I have authority to bind the Proponent.



SCHEDULE C - Pricing Sheet

Table 1: Budget by Deliverable.

Enter the budget against each milestone specified in Schedule E: Description of Goods and Services

Phase 1 - September 2020-December 2020 Kick off meeting (post contract signing) to set timelines, deliverables and scope Regularly scheduled working/engagement meetings through phase 1 (5) between proponent and Partnership staff Detailed workplan outlining key deliverable dates, analysis plan, and touchpoint meetings and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings to the Partnership and funded partners to the Partnership and fund	Deliverables	Start Date	End Date	Effort (In hours)	Cost
timelines, deliverables and scope Regularly scheduled working/engagement meetings through phase 1 (5) between proponent and Partnership staff Detailed workplan outlining key deliverable dates, analysis plan, and touchpoint meetings and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	Phase 1 - September 2020-December 2020				
Regularly scheduled working/engagement meetings through phase 1 (5) between proponent and Partnership staff Detailed workplan outlining key deliverable dates, analysis plan, and touchpoint meetings and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all qualitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	Kick off meeting (post contract signing) to set				
meetings through phase 1 (5) between proponent and Partnership staff Detailed workplan outlining key deliverable dates, analysis plan, and touchpoint meetings and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all qualitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	timelines, deliverables and scope				
proponent and Partnership staff Detailed workplan outlining key deliverable dates, analysis plan, and touchpoint meetings and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	Regularly scheduled working/engagement				
Detailed workplan outlining key deliverable dates, analysis plan, and touchpoint meetings and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all qualitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	meetings through phase 1 (5) between				
dates, analysis plan, and touchpoint meetings and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	proponent and Partnership staff				
and review times in collaboration with the Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
Partnership Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
Review and feedback presentation of final draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
draft qualitative tools with partners (virtual) Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	• • • • • • • • • • • • • • • • • • •				
Developed data collection tools 1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	·				
1 - focus group questions/facilitation guide 2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
2 - semi-structured interview guides incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	•				
incorporating engagement feedback 3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13					
3 - survey for participating clinicians Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13					
Phase 2 - January 2021- December 2021 Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
Qualitative data collection: 1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
1. Semi-structured interviews with 12-13 clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
clinician leads (virtual) 2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
2. Semi-structured interviews with 5-7 expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
expert coaches (virtual) 3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	· · · · · ·				
3. Up to 7 focus group sessions with project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
project teams at pre-scheduled dates (virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
(virtual) 4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	· · · · · · · · · · · · · · · · · · ·				
4 touch point meetings with the Partnership's Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	1				
Evaluation team (virtual) Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings	/				
Phase 3 - December 2021 - March 2022 Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
Analysis and synthesis of all quantitative data (data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
(data provided by the Partnership) Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
Analysis and synthesis of all qualitative data Presentation of preliminary evaluation findings					
Presentation of preliminary evaluation findings					
	to the Partnership and funded partners				



Meeting to discuss proposed outline of final				
evaluation outputs by proponent with the				
Partnership				
Output 1: Concise evaluation report				
summarizing the methods, findings and				
interpretation of the results	-			
Output 2: Final summary deck highlighting key messages				
Presentation of findings back to the				
Partnership				
Presentation of findings back to the funded				
partners and relevant stakeholders (virtual)				
Subtotal				
HST				
Total				
Additional Expenses Please provide a list of all additional expenses i costs, out of pocket expenses, transportation, fo		ut not lim	nited to: ac	dministrative
Total Proposed Price (Agreement Ceiling Price	e for fees)		\$	



SCHEDULE D - Reference Form

Form D1

Each Proponent should provide references from three (3) <u>different</u> clients (excluding the Partnership) who have obtained services similar to those required in this RFP from the Proponent within the last three (3) years.

The Partnership is not required to contact all references provided by the Proponent. In addition, references other than those provided by the Proponent (including but not limited to Partnership staff) may be contacted to obtain additional information that will be used in evaluating the Proponent's past performance.

Past performance will be evaluated on a pass/fail basis. Items to be evaluated include but is not limited to:

- 1. Conformance to contract requirements
- 2. Adherence to contract schedules
- 3. Cost Performance
- 4. Risk Management
- 5. Reasonable and Cooperative behavior (Business relations)
- 6. Commitment to Customer Service
- 7. Concern for the interest of the Customer

Proponent:	
Reference #1	
Company Name:	
Company Address:	
Contact Name:	
Contact Title:	
Contact Telephone Number & Email Address:	
Date Work Undertaken:	
Nature of Assignment:	
Reference #2	
Company Name:	
Company Address:	
Contact Name:	
Contact Title:	

Canadian Partnership Against Cancer RFP# RP430-2020-01 Issued: May 19, 2020



Contact Telephone Number &	
Email Address:	
Date Work Undertaken:	
Nature of Assignment:	
Reference #3	
Company Name:	
Company Address:	
Contact Name:	
Contact Title:	
Contact Telephone Number &	
Email Address:	
Date Work Undertaken:	
Nature of Assignment:	
1	



Form D2

Each Proponent should provide references from two (2) <u>different</u> clients (excluding the Partnership) to whom each candidate proposed for a key role has provided services <u>within</u> <u>the last three (3) years</u> in a role similar to that set out for the candidate in the Proposal.

	eparate copy of this part of the reference form for each
<mark>candidate proposed for each key r</mark>	ole set out in the Proposal.
Name of Candidate:	
Proposed Role:	
Reference #1	
Company Name:	
Company Address:	
Contact Name:	
Contact Title:	
Contact Telephone Number &	
Email Address:	
Date Work Undertaken:	
Nature of Assignment:	
•	
Reference #2	
Company Name:	
Company Address:	
Contact Name:	
Contact Title:	
Contact Telephone Number &	
Email Address:	
Date Work Undertaken:	
Nature of Assignment:	
-	

SCHEDULE E - Project Deliverables and Milestones

The Proponent should provide a detailed work plan, including the deliverables, timelines and project team responsibilities for the performance of the Agreement.

Deliverable/Milestone	Timeline	Responsibility

SCHEDULE F - Additional Terms and Conditions For Agreements

Background:

The funding for this Agreement provided by the Partnership is, in whole or in part, obtained pursuant to a funding agreement ("Health Canada Funding Agreement") between the Partnership and Her Majesty the Queen in Right of Canada as represented by the Minister of Health ("Minister");

The Health Canada Funding Agreement requires the Partnership to require certain minimum terms and conditions in agreements.

The Contractor acknowledges the source of the funding and recognizes the need to ensure that there is a high level of accountability and transparency in the receipt and expenditure of the funding.

The Parties agree that the following terms and conditions are included in addition to any other terms of the Agreement:

1. Definitions:

In this Agreement:

- "Agreement" means this agreement and all schedules and any amendments made to this agreement in accordance with its terms;
- b) "Amount" means the amount expressed in the Agreement to be payable to the Contractor for the Work;
- c) "Party" means the Partnership or the Contractor or any other signatory to the Agreement and "Parties" means all of them.

2. Accounts and Audit

- a) The Contractor shall keep proper and accurate Work-related accounts and records of the cost to the Contractor of the Work and of all expenditures or commitments made by the Contractor in connection therewith, and shall keep all invoices, receipts and vouchers relating thereto. The Contractor shall not, without the prior written consent of the Partnership, dispose of any such accounts and records, including invoices, receipts or vouchers, until the expiration of six (6) years after final payment under this Agreement, or until the settlement of all outstanding claims and disputes, whichever is later.
- b) All such accounts and records shall at all times during the retention period referred to in subsection a) be open to audit, inspection and examination by the authorized representatives of the Partnership, the Minister or the Auditor General of Canada to confirm compliance with this Agreement and the appropriate use of funds, who may make extracts from and/or make copies thereof. The Contractor shall provide access to its premises and

reasonable facilities for such audits, inspections and examinations and shall furnish all such information as the representatives may from time to time require with respect to such accounts and records. The Partnership shall be entitled to monitor and review the Work through site visits or other means.

3. Appropriation

Each payment to be made under the Agreement at any given time is subject to the Partnership having been provided sufficient funding from the Minister for the fiscal year in which the payment is due.

4. Assignment

- a) The Contractor shall not assign this Agreement or any payment, right or obligation hereunder without the prior written consent of the Partnership. Any assignment made without that prior written consent is void and of no effect.
- b) No assignment of this Agreement shall relieve the Contractor from any obligation under this Agreement or impose any liability upon the Partnership unless otherwise agreed to in writing by the Partnership. This Agreement binds the Parties and their respective successors and permitted assigns.

5. Changes

- a) If, on the basis of progress reports provided to the Partnership or for any other reason, the Parties decide that modifications to the Work or to line items within the budget are needed, the appropriate changes may be made by the administrative contact for the Parties, provided that no increase shall be made to the maximum Amount payable hereunder and further provided that no other term of this Agreement may be altered in this fashion.
- b) If the change is greater than 15% or \$50,000 of the maximum Amount payable, whichever is lesser, or if the maximum Amount payable changes, the formal amendment process, signed by the approved delegated authority, shall apply.
- c) If the Partnership, acting reasonably, determines that modifications to the Work are needed (including substituting deliverables), the Contractor shall use commercially reasonable efforts to accommodate the Partnership's request for modifications in a manner that avoids changing the maximum Amount payable.

6. Communications

a) If this Agreement requires work with members of the public, the Contractor shall take the necessary measures

- to respect the spirit and intent of the *Official Languages Act* to communicate with the public in the official language (i.e., English or French) of their choice;
- b) Any person related to the Contractor shall, where ensure that: (i) communication, appropriate, announcements or documents for the general public concerning services, programs, projects or activities are provided in both official languages; (ii) any services, programs, projects or activities to be delivered by the Contractor to the general public are delivered in both official languages; (iii) any services provided to official language minority communities are provided in a manner that they may participate in these services on a basis comparable to the majority language community; and (iv) consultations with stakeholders on services, programs, projects or activities encourage participation in both official languages, as well as representatives from official language minority communities.

7. Compliance with Applicable Laws

The Contractor shall comply with all applicable laws, regulations and policies relating to the performance of the Work including, without limitation, those concerning privacy and confidentiality, health and labour conditions and the protection of the environment, and shall require compliance therewith by all of its subcontractors. Evidence of compliance with such laws shall be furnished by the Contractor to the Partnership at such times as the Partnership may reasonably request.

8. Confidentiality

- a) The Contractor shall keep confidential all information provided to the Contractor by or on behalf of the Partnership in connection with this Agreement, or acquired by the Contractor in the course of performing the Work. The Contractor shall not disclose the information to any person without the written permission of the Partnership, except that the Contractor may disclose to a subcontractor, authorized in accordance with this Agreement, information necessary for the performance of the subcontract. The Contractor shall treat as confidential and cause those with whom it shares such information, during as well as after the performance of any Work under this Agreement, any information to which the Contractor becomes privy as a result of acting under the Agreement.
- b) This section does not apply to any information that:
 - i. is publicly available from a source other than the Contractor:
 - ii. is or becomes known to the Contractor from a source other than the Partnership, except any source that is known to the Contractor to be under an obligation to the Partnership not to disclose the information; or

- iii. is required to be disclosed by law or by court or other lawful authority.
- c) If the Contractor is required, by law or by a court or other lawful authority, to disclose the Partnership's confidential information, the Contractor shall: promptly notify the Partnership before making any such disclosure, if such notification is not prohibited by law, the court or other lawful authority; cooperate with the Partnership on the proposed form and nature of the disclosure; and ensure that any disclosure is made in accordance with the requirements of applicable law and within the parameters of the specific requirements of the court or other lawful authority.
- d) Upon request, the Contractor shall return to the Partnership all information provided to the Contractor by or on behalf of the Partnership or acquired by the Contractor in connection with the Work and any copies of the information, in any form whatsoever.

9. Conflict of Interest and Government Contracting

- a) The Contractor represents and warrants that the Contractor has no interest in the business of any third party that would cause a conflict of interest or seem to cause a conflict of interest in carrying out the Work. Should such an interest be acquired during the Term, the Contractor shall declare it immediately to the Partnership.
- b) It is a term of this Agreement that no individual who is subject to the provisions of the Conflict of Interest Act, the Conflict of Interest Code for Members of the House of Commons, the Conflict of Interest Code for Senators, the Conflict of Interest and Post-Employment Code for Public Office Holders, the Values and Ethics Code for Health Canada, the Values and Ethics Code for the Public Sector or any other values and ethics codes applicable within provincial or territorial governments or specific organizations shall derive a direct benefit resulting from this Agreement unless the provision or receipt of such benefit is in compliance with such legislation and codes.
- c) The Contractor represents and warrants that the Contractor, and the Contractor's officers, agents and employees, are not prohibited under subsection 750(3) of the Criminal Code from benefiting from a government contract.
- d) The Contractor represents, warrants and covenants that no bribe, gift, benefit or other inducement has been or will be paid, given, promised or offered directly or indirectly to any official or employee of the Partnership or to a member of the family of such a person with a view to influencing the entry into this Agreement or the administration of this Agreement.
- e) The Contractor acknowledges and agrees that the Partnership will provide the Minister with access to this Agreement.

10. Relationship of the Parties

Nothing contained in this Agreement creates or shall be construed to create a relationship of principal-agent, employer-employee, partnership or joint venture between the Parties. The Contractor shall not represent itself (including in any agreement with any third party) as the agent, employee or partner of the Partnership or in a manner that could lead a member of the public to believe that the Contractor is an agent, employee or partner of the Partnership. The Contractor shall be solely responsible for any and all deductions and payments required to be made from or to employees, including those required for Canada or Quebec pension plans, employment insurance, worker's compensation and income tax.

11. Dispute Resolution

If the Parties have a dispute relating to any matter subject to this Agreement, the Parties shall deal with that dispute through court action.

12. Entire Agreement

The Agreement, including its schedules, constitutes the entire Agreement between the Parties with respect to its subject matter and supersedes all previous agreements, understandings, negotiations and discussions, both oral and written, between the Parties unless they are incorporated by reference in this Agreement. All amendments to this Agreement are to be made in writing and signed by the Parties.

13. Further Assurances

The Contractor shall do, execute and deliver, or cause to be done, executed and delivered, all such further assignments, documents, instruments, transfers, acts, deeds, matters, assurances and things as, from time to time, may be reasonably necessary or desirable to give effect to this Agreement.

14. Indemnification

a) The Contractor shall indemnify and save harmless the Partnership and its directors, officers, employees, agents, successors and assigns from and against all claims, losses, damages, costs, expenses, including solicitor/client fees, administrative fees and disbursements, causes of action, actions and other proceedings ("Claims"), made, sustained, brought, prosecuted, threatened to be brought or prosecuted, in any manner based upon, occasioned by, or attributable to, any environmental effect, injury to or death of a person or damage to or loss of property, arising directly or indirectly from any act, omission or delay on the part of the Contractor or the Contractor's employees or agents in performing the Work or as a result of the

Work, and any liens, attachments, charges or other encumbrances or claims upon or in respect of any materials, parts, work-in-process or finished work furnished to, or in respect of which any payment has been made by the Partnership and for the use of an invention claimed in a patent, or infringement or alleged infringement of any patent or any registered industrial design or any copyright or trade secret resulting from the performance of the Contractor's obligations under this Agreement, and in respect of the use of or disposal by the Partnership of anything furnished pursuant to this Agreement, except that the Partnership will not claim indemnification under this section to the extent that the injury, loss or damage has been caused by the Partnership or its employees or agents.

- b) The Contractor's obligation of indemnity or reimbursement of the Partnership under this Agreement shall not affect or prejudice the Partnership from exercising any other rights it has under law.
- c) To the extent that any third party, in reliance upon representations made by the Contractor, considers the Contractor to be an agent or employee of the Partnership, the Contractor shall indemnify and save harmless the Partnership for any Claims occasioned thereby by such third party.
- d) The Contractor shall protect itself, through an appropriate policy of insurance, against any liability resulting from anything done or omitted to be done by the Contractor in carrying out the Work under this Agreement, for such coverage limits as a reasonably prudent party carrying out the same or similar activities might obtain.

15. Injury on Duty

The Partnership shall assume no liability for injury on duty while the Contractor is performing tasks related to this Agreement except to the extent caused by or due to the Partnership. It is the Contractor's responsibility to ensure that proper insurance coverage is in place prior to the commencement of the Work.

16. Inspection of the Work

a) The Work and any and all parts thereof shall be subject to such inspection as the Partnership determines to be appropriate, consistent with the relevant provisions of this Agreement, if any, prior to acceptance. The Partnership or its representatives, shall have access to the Work at any time during working hours at any site where any part of the Work is being carried out and may make examinations and such tests of the Work as they may think fit. Should the Work or any part thereof not be in accordance with the requirements of the Agreement, the Partnership shall have the right to reject the Work and require its correction or replacement at the Contractor's expense. The Partnership shall inform the Contractor of the reasons for any such rejection.

- b) The Contractor shall provide all assistance and facilities, test pieces, samples and documentation that the Partnership may reasonably require for the carrying out of any such inspection, and the Contractor shall forward such test pieces and samples to such person or location as the Partnership may direct. Inspection by the Partnership shall not relieve the Contractor from responsibility to meet the requirements of this Agreement.
- c) No part of the Work shall be submitted for acceptance or delivery until it has been inspected and approved by the Contractor and, wherever practicable, marked with an approval stamp satisfactory to the Partnership. The Contractor shall keep accurate and complete inspection records which shall, upon request, be made available to the Partnership, which may make copies thereof and take extracts therefrom during the performance of this Agreement and for any period of time thereafter provided for in this Agreement.

17. Intellectual Property

- a) Intellectual property developed for this Agreement shall vest in and be owned by the Partnership.
- b) The Partnership shall have a nonexclusive royalty-free sub-licensable right to use any other intellectual property of the Contractor required to use the intellectual property developed for this Agreement.

18. Invoicing

- a) The Contractor shall submit invoice(s) on its own forms to the Partnership, which shall include the following information:
 - i. Contractor name and address;
 - ii. Number assigned by the Partnership, if any, to this Agreement;
 - iii. Contractor's Invoice Number and Date;
 - iv. Name of the individual at the Partnership supervising this Agreement;
 - v. Period in which services were rendered;
 - vi. Deliverables and/or milestones completed and attached (when applicable); and
 - vii. Total amount for services rendered, HST shown separately.
- b) The invoice submitted by the Contractor should include a description of the Work performed, and the time worked. The Contractor will submit invoices on a monthly basis or any other basis as indicated in this Agreement.

19. Language

The parties confirm it is their wish that this Agreement be drawn up in the English Language. Les parties conferment

qu'ils souhaitent que le présent accord soit rédigé en anglais.

20. Governing Laws

The Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein. The Parties shall submit to the jurisdiction of the courts sitting in Toronto, Ontario.

21. Minimum Information in this Agreement

This Agreement shall include the following minimum information:

- a) a description of the Work, a budget, the Amount to be paid and clear expectations as to the results expected through carrying out the Work;
- the effective date, the date of signing and the term of this Agreement;
- c) conditions that must be met before payment is made and the schedule and basis of payment; and
- d) the maximum amount payable.

If at any time it is discovered that this Agreement does not contain all or any part of the minimum information required, the Parties shall use their best efforts in good faith to amend this Agreement to include the information that is missing.

22. Notices

Where in this Agreement any notice, demand, request, direction or other communication is required to be given or made by a Party, it shall be in writing and is effective if sent by any means, including electronic means, addressed to the Party for whom it is intended at the address mentioned in this Agreement, and any such communication shall be deemed to have been received if by registered mail, when the postal receipt is acknowledged by the Party, if by electronic means, one business day after having been sent and if by mail, five business days after being mailed. The address of a Party may be changed by notice in the manner set out in this provision.

23. Payment

- a) Payments under this Agreement, except advance payments, shall be conditional upon performance, completion and delivery of the Work, or any part of the Work, to the satisfaction of the Partnership, and upon submission of an invoice satisfactory to the Partnership.
- b) Subject to the section "Invoicing", payment by the Partnership for the Work shall be made within sixty (60) days of receipt of an invoice requesting payment.

- c) If the Partnership has any reasonable objection whatsoever to an invoice, the supporting documentation or the performance of this Agreement by the Contractor, then the Partnership shall, within fifteen (15) days of receipt of the invoice or as quickly as reasonably possible, notify the Contractor of the nature of the objection.
- d) Notwithstanding any other provision of this Agreement, no payment shall be made to the Contractor unless and until, with respect to all parts of the Work in respect of which payment is claimed, the Contractor, where required to do so, establishes to the satisfaction of the Partnership that such parts of the Work will be free from all claims, liens, attachments, charges or encumbrances.

24. Powers of the Partnership

Every right, remedy, power and discretion vested in or acquired by the Partnership under this Agreement or by law shall be cumulative and non-exclusive.

25. Proactive Disclosure

- a) Information contained in this Agreement in relation to the following data elements: Contractor name, reference number, Agreement date, description of Work, Agreement period or delivery date, and Agreement value, may be posted on the Partnership's website. Information that would normally be withheld under the Access to Information Act and Privacy Act will not appear on the website.
- b) This "public disclosure" is intended to ensure that Agreement information is collected and presented consistently in a manner that promotes transparency and facilitates public access.

26. Reporting

- a) The Contractor shall provide the Partnership with such progress reports, including financial matters, as are called for on the Work under this Agreement and, in any event, no less frequently than annually for the period ending March 31 of each year. Unless otherwise provided in this Agreement, the form and substance of the progress report shall be acceptable to the Partnership.
- b) The Partnership may, in its sole discretion, require the Contractor to provide an interim progress report on the Work for a specified period of time (no more than a 12 month period).
- c) The Partnership may withhold or reduce any payments to be made to the Contractor under this Agreement if any report has not be submitted by the Contractor in accordance with the requirements of this Agreement.

27. Severability

If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, by a court of competent jurisdiction, such invalidity or unenforceability shall not affect the remaining terms or provisions of this Agreement.

28. Status and Replacement of Personnel

- a) If at any time during the Term the Contractor is unable to provide the services of any person who was to perform the Work, it shall immediately advise the Partnership and provide a replacement person with similar qualifications and experience.
- b) The Partnership may reject any such replacement person and the Contractor shall immediately remove the person from the Work and shall secure a further replacement.
- c) The fact that the Partnership does not order the removal of a replacement person from the Work shall not relieve the Contractor from its responsibility to meet the requirements of the Agreement.

29. Subcontracting

- a) Unless otherwise provided in this Agreement, the Contractor shall obtain the consent of the Partnership in writing prior to subcontracting or permitting the subcontracting of any portion of the Work at any time. The Partnership shall not unreasonably withhold consent.
- b) The Contractor is not obliged to seek consent to subcontracts specifically authorized in this Agreement.
- c) Any consent to a subcontract shall not relieve the Contractor from its obligations under this Agreement or be construed as authorizing any liability on the part of the Partnership to a subcontractor.

30. Survival

All obligations of the Contractor shall expressly, or by their nature, survive expiry or termination of this Agreement until, and unless, they are fulfilled, or by their nature expire.

31. Termination Due to Default

- a) The Partnership may, by notice to the Contractor, terminate this Agreement if:
 - i. the Contractor becomes insolvent or commits an act of bankruptcy, makes an assignment for the benefit of creditors or takes the benefit of any statute relating to bankrupt or insolvent debtors, goes into receivership or bankruptcy, ceases to carry on business, or is wound up or dissolved;
 - ii. the Contract has made materially false or misleading representations or statements, or provided materially false or misleading information to the Partnership on any matter related to this Agreement, other than in good faith (the Contractor shall demonstrate good faith):
 - iii. the Contractor fails to perform or comply with any term, condition or obligation under this Agreement; or

- iv. in the opinion of the Partnership, the Contractor fails to proceed diligently with the Work so as to jeopardize performance of this Agreement in accordance with its terms.
- b) If the Partnership terminates this Agreement under subsection a), the Partnership may arrange, upon such terms and conditions and in such manner as the Partnership deems appropriate, for the Work to be completed that was so terminated, and the Contractor shall be liable to the Partnership for any excess costs relating to the completion of the Work.
- Upon termination of this Agreement under sub-section a), the Partnership may require the Contractor to deliver and transfer title to the Partnership, in the manner and to the extent directed by the Partnership, any finished work that has not been delivered and accepted prior to such termination and any materials or work-in-process that the Contractor has specifically acquired or produced for the fulfillment of the Agreement. The Partnership shall pay the Contractor for all finished work delivered pursuant to such direction and accepted by the Partnership, the cost to the Contractor of such finished work plus the proportionate part of any fee fixed by this Agreement and shall pay or reimburse the Contractor the fair and reasonable cost to the Contractor of all materials or workin-process delivered to the Partnership pursuant to such direction. The Partnership may withhold from the amounts due to the Contractor such sums as the Partnership determines to be necessary to protect the Partnership against excess costs for the completion of the Work. Such termination shall not impact the intellectual property rights available from Contractor under section 18 as in existence to the date of termination.
- d) The Contractor shall not be entitled to be reimbursed any amount which, taken together with any amounts paid or becoming due to the Contractor under this Agreement, exceeds the Amount applicable to the Work or the particular part thereof.
- e) If, after the Partnership issues a notice of termination under subsection a), it is determined by the Partnership that the default of the Contractor is due to causes beyond the control of the Contractor, such notice of termination shall be deemed to have been issued pursuant to the section entitled "termination or Suspension Without Cause" and the rights and obligations of the Parties shall be governed by that section.

32. Termination or Suspension Without Cause

a) The Partnership may, by giving notice to the Contractor, terminate or suspend the Work with respect to all or any part or parts of the Work not completed. The Contractor shall proceed to complete parts of the Work not affected

- by the termination notice. Additional notices for different parts of the Agreement may be given subsequently.
- b) All Work completed by the Contractor to the satisfaction of the Partnership based on the provisions of this Agreement before the giving of such notice shall be paid for by the Partnership in accordance with the provisions of this Agreement.
- c) All Work not completed by the Contractor to the satisfaction of the Partnership based on the provisions of this Agreement before the giving of such notice shall be paid for by the Partnership to the Contractor on the following terms:
 - i. the amount of any capital expenditures actually incurred only if they were specifically authorized under the Agreement or approved in writing by the Partnership for the purpose of the Agreement, less any depreciation in respect thereof already taken into account in determining cost, to the extent that the capital expenditures are properly apportionable to the performance of this Agreement;
 - ii. all costs of and incidental to the termination of this Agreement, including the cost of cancellation of obligations incurred by the Contractor with respect to the terminated Work or part thereof; but not including the cost of severance payments or damages to employees whose services are no longer required by reason of the termination.
- d) Payment and reimbursement under the provisions of this section shall be made only to the extent that it is established to the satisfaction of the Partnership that the costs and expenses were actually incurred by the Contractor and that the same are fair and reasonable and are properly attributable to the termination or suspension of the Work or the part thereof so terminated.
- e) The Contractor shall not be entitled to be reimbursed any amount which, taken together with any Amounts paid or becoming due to the Contractor under this Agreement, exceeds the Amount applicable to the Work or the particular part thereof.
- f) The Contractor shall have no claim for damages, compensation, loss of profit, allowance or otherwise by reason of or directly or indirectly arising out of any action taken or notice given by the Partnership under the provisions of this section except as expressly provided therein.

33. Time of the Essence

- a) Time is of the essence of this Agreement.
- Any delay by the Contractor in performing the Contractor's obligations under this Agreement which is caused by an event beyond the control of the Contractor, and which could not have been foreseen and could not

have been avoided by the Contractor by means reasonably available to the Contractor, constitutes an excusable delay. Events may include, but are not restricted to: acts of God, acts of Her Majesty, acts of local or provincial governments, fires, floods, epidemics, quarantine restrictions, strikes or labour unrest, freight embargoes and unusually severe weather.

- c) The Contractor shall give notice to the Partnership immediately after the occurrence of the event that causes the excusable delay. When requested to do so by the Partnership, the Contractor shall deliver a description in a form satisfactory to the Partnership, of work-around plans including alternative sources and any other means that the Contractor will utilize to overcome the delay and endeavour to prevent any further delay. Upon approval in writing by the Partnership of the work-around plans, the Contractor shall implement the work-around plans and use all reasonable means to recover any time lost as a result of the excusable delay. Any additional costs caused by the delay shall be supported by the Contractor.
- d) Notwithstanding that the Contractor has complied with the requirements of this section, the Partnership may exercise any right of termination contained in the section entitled "Termination or Suspension Without Cause".

34. Waivers

The fact that the Partnership refrains from exercising a remedy or right that it is entitled to exercise under this Agreement shall not be considered to be a waiver of such remedy or right and, furthermore, partial or limited exercise of a remedy or right conferred on the Partnership shall not prevent it in any way from later exercising any other remedy or right under this Agreement or applicable law, unless the Partnership waives such remedy or right in writing.

35. Warranty

- a) Notwithstanding inspection and acceptance of the Work by or on behalf of the Partnership and without restricting any other provision of this Agreement or any condition, warranty or provision implied or imposed by law, the Contractor warrants that, for a period of 12 months from the date of delivery, or if acceptance takes place on a later date, the date of acceptance, the Work shall be free from all defects in design, materials or workmanship, and shall conform with the requirements of this Agreement, provided that with respect to property provided by the Partnership, the Contractor's warranty shall extend only to its proper incorporation into the Work. In addition, the Contractor has the obligation to respect any other warranty provided for by law.
- In the event of a defect or non-conformance in any part of the Work during the warranty period defined in

subsection a) the Contractor, at the request of the Partnership to do so, shall as soon as possible repair, replace or otherwise make good at its own option and expense the part of the Work found to be defective or not in conformance with the requirements of this Agreement.

36. Counterparts

This Agreement may be signed in counterparts and each counterpart shall constitute an original document and all counterparts taken together shall constitute one and the same Agreement.